On June 6, 2022 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, reported that presentation of a poster at the ASCO (Free ASCO Whitepaper) Annual Meeting to be held from 3rd – 8th June 2022 (Press release, BerGenBio, JUN 6, 2022, View Source [SID1234615622]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation provides clinical data from a Phase 1 dose escalation and expansion study of bemcentinib (BGB324) in combination with docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). The data presented indicate that bemcentinib in combination with docetaxel shows evidence of anti-tumor activity, with 35% of patients achieving a partial response and 47% attaining stable disease, and a manageable safety profile in previously treated, advanced NSCLC.

Cristina Oliva, Chief Medical Officer at BerGenBio, commented: "While the data are limited, they suggest a mechanism by which treatment with bemcentinib could delay resistance to and potentiate the effects of chemotherapy treatment in NSCLC patients."

The full abstract is available on the ASCO (Free ASCO Whitepaper) website here: View Source